Isofol Medical AB

Isofol Medical Advances Arfolitixorin Development with New Phase Ib/II Trial for Metastatic Colorectal Cancer

2 months ago

• Isofol Medical has received regulatory approval to initiate a Phase Ib/II clinical trial evaluating arfolitixorin in first-line treatment of metastatic colorectal cancer at Germany's prestigious Charité Universitätsmedizin Berlin. • The new study implements an optimized dosing regimen with higher doses administered earlier in the treatment cycle, designed to enhance arfolitixorin's synergistic effects with 5-FU chemotherapy. • The trial will replace leucovorin with arfolitixorin in standard treatment protocols and will be conducted in two stages: dose escalation assessment followed by efficacy comparison between selected dosages.

Arfolitixorin Shows Promise in Post-Hoc Analysis of Phase III AGENT Trial for Colorectal Cancer

4 months ago

A new post-hoc analysis of the Phase III AGENT study, presented at ASCO GI 2025, reveals favorable outcomes for arfolitixorin in colorectal cancer treatment, particularly in North America where it achieved an 85.7% objective response rate compared to 45.5% with leucovorin. The analysis suggests that protocol compliance and regional differences in treatment administration significantly impacted the study's outcomes.